These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 24103274)

  • 1. Diagnostic accuracy of K-ras mutation for pancreatic carcinoma: a meta-analysis.
    Liu SL; Chen G; Zhao YP; Wu WM; Zhang TP
    Hepatobiliary Pancreat Dis Int; 2013 Oct; 12(5):458-64. PubMed ID: 24103274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of K-ras gene mutation analysis in EUS-guided FNA cytology specimens for the differential diagnosis of pancreatic solid masses: a meta-analysis of prospective studies.
    Fuccio L; Hassan C; Laterza L; Correale L; Pagano N; Bocus P; Fabbri C; Maimone A; Cennamo V; Repici A; Costamagna G; Bazzoli F; Larghi A
    Gastrointest Endosc; 2013 Oct; 78(4):596-608. PubMed ID: 23660563
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic alterations of K-ras, p53, c-erbB-2, and DPC4 in pancreatic ductal adenocarcinoma and their correlation with patient survival.
    Shin SH; Kim SC; Hong SM; Kim YH; Song KB; Park KM; Lee YJ
    Pancreas; 2013 Mar; 42(2):216-22. PubMed ID: 23344532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fluorescence in situ hybridization and K-ras analyses improve diagnostic yield of endoscopic ultrasound-guided fine-needle aspiration of solid pancreatic masses.
    Reicher S; Boyar FZ; Albitar M; Sulcova V; Agersborg S; Nga V; Zhou Y; Li G; Venegas R; French SW; Chung DS; Stabile BE; Eysselein VE; Anguiano A
    Pancreas; 2011 Oct; 40(7):1057-62. PubMed ID: 21705950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. K-Ras mutation detection in liquid biopsy and tumor tissue as prognostic biomarker in patients with pancreatic cancer: a systematic review with meta-analysis.
    Li T; Zheng Y; Sun H; Zhuang R; Liu J; Liu T; Cai W
    Med Oncol; 2016 Jul; 33(7):61. PubMed ID: 27225938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pancreatic cyst fluid DNA analysis in evaluating pancreatic cysts: a report of the PANDA study.
    Khalid A; Zahid M; Finkelstein SD; LeBlanc JK; Kaushik N; Ahmad N; Brugge WR; Edmundowicz SA; Hawes RH; McGrath KM
    Gastrointest Endosc; 2009 May; 69(6):1095-102. PubMed ID: 19152896
    [TBL] [Abstract][Full Text] [Related]  

  • 7. K-ras mutations in the plasma correspond to computed tomographic findings in patients with pancreatic cancer.
    Däbritz J; Preston R; Hänfler J; Oettle H
    Pancreas; 2012 Mar; 41(2):323-5. PubMed ID: 22044911
    [No Abstract]   [Full Text] [Related]  

  • 8. K-ras mutations in circulating DNA from pancreatic and lung cancers: bridging methodology for a common validation of the molecular diagnosis value.
    Magistrelli P; Neri M; Granone P; Cesario A; Paleari L; Russo P
    Pancreas; 2008 Jul; 37(1):101-2. PubMed ID: 18580451
    [No Abstract]   [Full Text] [Related]  

  • 9. A meta-analysis of the diagnostic value of detecting K-ras mutation in pancreatic juice as a molecular marker for pancreatic cancer.
    Yang J; Li S; Li J; Wang F; Chen K; Zheng Y; Wang J; Lu W; Zhou Y; Yin Q; Zhang H; Guo C
    Pancreatology; 2016; 16(4):605-14. PubMed ID: 27237100
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Impact of KRAS and GNAS Analysis Added to CEA and Cytology in Pancreatic Cystic Fluid Obtained by EUS-FNA.
    Faias S; Duarte M; Albuquerque C; da Silva JP; Fonseca R; Roque R; Dias Pereira A; Chaves P; Cravo M
    Dig Dis Sci; 2018 Sep; 63(9):2351-2361. PubMed ID: 29796909
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance of K-ras mutations in pancreatic cancer: a meta-analysis.
    Tao LY; Zhang LF; Xiu DR; Yuan CH; Ma ZL; Jiang B
    World J Surg Oncol; 2016 May; 14():146. PubMed ID: 27183870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. KRAS mutations in codon 12 or 13 are associated with worse prognosis in pancreatic ductal adenocarcinoma.
    Sinn BV; Striefler JK; Rudl MA; Lehmann A; Bahra M; Denkert C; Sinn M; Stieler J; Klauschen F; Budczies J; Weichert W; Stenzinger A; Kamphues C; Dietel M; Riess H
    Pancreas; 2014 May; 43(4):578-83. PubMed ID: 24681874
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the diagnostic value of serum tumor markers, and fecal k-ras and p53 gene mutations for pancreatic cancer.
    Wu X; Lu XH; Xu T; Qian JM; Zhao P; Guo XZ; Yang XO; Jiang WJ
    Chin J Dig Dis; 2006; 7(3):170-4. PubMed ID: 16808798
    [TBL] [Abstract][Full Text] [Related]  

  • 14. K-ras mutational status in cytohistological tissue as a molecular marker for the diagnosis of pancreatic cancer: a systematic review and meta-analysis.
    Yang J; Li J; Zhu R; Zhang H; Zheng Y; Dai W; Wang F; Shen M; Chen K; Cheng P; Zhang Y; Wang C; Wang J; Xia Y; Lu J; Zhou Y; Guo C
    Dis Markers; 2014; 2014():573783. PubMed ID: 25301978
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RAS mutations in indeterminate thyroid nodules are predictive of the follicular variant of papillary thyroid carcinoma.
    An JH; Song KH; Kim SK; Park KS; Yoo YB; Yang JH; Hwang TS; Kim DL
    Clin Endocrinol (Oxf); 2015 May; 82(5):760-6. PubMed ID: 25109485
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endoscopic ultrasound-guided fine-needle aspiration biopsy coupled with a KRAS mutation assay using allelic discrimination improves the diagnosis of pancreatic cancer.
    Bournet B; Selves J; Grand D; Danjoux M; Hanoun N; Cordelier P; Buscail L
    J Clin Gastroenterol; 2015 Jan; 49(1):50-6. PubMed ID: 24798941
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of K-ras mutation status and subtypes in endoscopic ultrasound-guided fine-needle aspiration specimens from patients with unresectable pancreatic cancer.
    Ogura T; Yamao K; Hara K; Mizuno N; Hijioka S; Imaoka H; Sawaki A; Niwa Y; Tajika M; Kondo S; Tanaka T; Shimizu Y; Bhatia V; Higuchi K; Hosoda W; Yatabe Y
    J Gastroenterol; 2013 May; 48(5):640-6. PubMed ID: 22983505
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decreased expression of DAB2IP in pancreatic cancer with wild-type KRAS.
    Duan YF; Li DF; Liu YH; Mei P; Qin YX; Li LF; Lin QX; Li ZJ
    Hepatobiliary Pancreat Dis Int; 2013 Apr; 12(2):204-9. PubMed ID: 23558076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Usefulness of p16 and K-ras mutation in pancreatic adenocarcinoma and chronic pancreatitis differential diagnosis.
    Talar-Wojnarowska R; Gasiorowska A; Smolarz B; Romanowicz-Makowska H; Strzelczyk J; Janiak A; Kulig A; Malecka-Panas E
    J Physiol Pharmacol; 2004 Jul; 55 Suppl 2():129-38. PubMed ID: 15608367
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of K-RAS and B-RAF mutations as biomarkers in metastatic colorectal cancer.
    Selcukbiricik F; Erdamar S; Ozkurt CU; Molinas Mandel N; Demirelli F; Ozguroglu M; Tural D; Buyukunal E; Serdengecti S
    J BUON; 2013; 18(1):116-23. PubMed ID: 23613396
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.